NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone
Ionis Pharmaceuticals (IONS) stock is in focus after the company completed enrollment in the pivotal pediatric cohort of its global Phase 3 REVEAL study of obudanersen for Angelman syndrome, a rare neurodevelopmental disorder.
See our latest analysis for Ionis Pharmaceuticals.
The recent pediatric cohort milestone for obudanersen comes on top of an eventful few weeks for Ionis Pharmaceuticals, including FDA approval of TRYNGOLZA and a new zilganersen licensing deal. During this period the...